A new drug may change the landscape of melanoma treatment, offering patients a treatment option that goes beyond anything previously used against the skin cancer, new research shows. Tests in people whose melanoma had spread show the drug was able to shrink tumors in most patients and, in a few cases, even wiped the growths out, scientists report in the Aug. 26 New England Journal of Medicine. The compound targets the protein encoded by a mutated version of the BRAF gene that underlies melanoma in roughly half of all patients.
“This demonstrates for the first time that a targeted therapy can work in melanoma,” says Richard Marais, a molecular biologist at the Institute of Cancer Research in London. “This is an enormous advance in the field. It’s just unparalleled.”
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.